CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Medical Coverage Policy Saturation Biopsyfor Diagnosis, Staging and Management of Prostate Cancer

Policy governs coverage for saturation prostate biopsy (generally >20 cores, transrectal or transperineal stereotactic template-guided) when used for diagnosis, staging, or management (including active surveillance) of prostate cancer for commercial and Medicare Advantage products.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMedical Coverage Policy Saturation Biopsyfor Diagnosis, Staging and Management of Prostate Cancer

Policy CodePolicy N/A

Change Typeclarified

Effective DateOct 1, 2015

Next Review Date

Key ActionWhen performing saturation biopsy, claims should not be filed with codes 55700 or G0416 because these are not specific to saturation sampling; use CPT 55706 if applicable but policy deems saturation not medically necessary.

SourceLink

POLICY UPDATE CHANGES

Policy last updated 11/23/2021 and published in Provider Update January 2022; no clinical policy statement changes indicated.

1Coverage stance (not medically necessary)

1Specific CPT code listed for saturation

2Codes explicitly not to be used when filing saturation

Coverage Summary

Saturation prostate biopsy (generally defined as obtaining more than 20 cores, performed transrectally or as a transperineal stereotactic template-guided procedure) is addressed for use in the diagnosis, staging, and management (including active surveillance) of prostate cancer. The policy effective date is 10/01/2015 and the policy was last reviewed/updated on 11/23/2021 and published in the Provider Update in January 2022.

Surface thresholds and quick facts

Saturation biopsy definition (cores)Generally more than 20 cores

Coverage stanceNot medically necessary / not covered for diagnosis, staging, and management of prostate cancer

Specific CPT code listed for saturation55706 (transperineal stereotactic template saturation sampling, including imaging guidance)

Codes explicitly NOT to be used when filing saturation55700 (needle biopsy, single or multiple) and G0416 (prostate biopsy, repeat limited or other)

Policy effective/last reviewedEffective 10/01/2015; Policy last updated 11/23/2021

Medical Necessity and Coverage Determinations

Policy Statement / Coverage Determination

Saturation biopsy coverage determination:

Not covered determination: Saturation biopsy is not covered for diagnosis, staging, and management of prostate cancer because evidence is insufficient to demonstrate improvement in net health outcome
Commercial products determination: Commercial Products: Saturation biopsy is considered not medically necessary in the diagnosis, staging and management of prostate cancer

ref_bucket_hashes_representation_for_webui_testing_ignore_me_do_not_use_change_or_depend_on_this_field_please_ignore_it_2c7b4f2a8bc9c5f7c0d6f9e3a4b1c0d7e8f9a0b1c2d3e4f5a6b7c8d9e0f1a2b3c4d5e6f7a8b9c0d1e2f3a4b5c6d7e8f9a0b1c2d3e4f5a6b7c8d9e0f1a2b3c4d5e6f7a8b9c0d1e2f3a4b5c6d7e8f9a0b1c2d3e4f5a6b7c8d9e0f1a2b3c4d5e6f7a8b9c0d1e2f3a4b5c6d7e8f9a0b1c2d3e4f5a6b7c8d9e0f1a2b3c4d5e6f7a8b9c0d1e2f3a4b5c6d7e8f9a0b1c2d3e4f5a6b7c8d9e0

ref_origination_id_for_webui_testing_ignore_me_do_not_use_change_or_depend_on_this_field_please_ignore_it_9f1a2b3c4d5e6f7081920a1b2c3d4e5f6a7b8c9d0e1f2a3b4c5d6e7f8091a2b3c4d5e6f7081920a1b2c3d4e5f6a7b8c9d0e1f2a3b4c5d6e7f8091a2b3c4d5e6f7a8b9c0d1e2f3a4b5c6d7e8f9a0b1c2d3e4f5a6b7c8d9e0f1

ref_repr_sha256_for_webui_testing_ignore_me_do_not_use_change_or_depend_on_this_field_please_ignore_it_e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

ref_source_lineage_for_webui_testing_ignore_me_do_not_use_change_or_depend_on_this_field_please_ignore_it_aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa

ref_origins_for_webui_testing_ignore_me_do_not_use_change_or_depend_on_this_field_please_ignore_it_b1_0

ref_text_fingerprint_for_webui_testing_ignore_me_do_not_use_change_or_depend_on_this_field_please_ignore_it_5d41402abc4b2a76b9719d911017c592

title": "Policy Statement / Coverage Determination"

ref": "b1_0

Medical Criteria

Medical necessity criteria:

Medical Criteria: Medical criteria: Not applicable (policy states saturation biopsy is not medically necessary)

Prior Authorization

Prior authorization requirement:

Prior Authorization: Prior authorization: Not applicable

Coding

Specific CPT code for saturation sampling (listed)CPT

55706

Biopsies, prostate, needle, transperineal, stereotactic template saturation sampling, including imaging guidance

Codes not to be used for saturation claimsmixedNot Covered

55700	Biopsies, prostate; needle, single or multiple, any approach (not specific to saturation sampling) - not to be filed when performing saturation
G0416	Prostate biopsy, repeat limited or other (not specific to saturation sampling) - not to be filed when performing saturation

Provider Actions / Billing Guidance

Billing Rule

Do not file non-specific codes for saturation

When performing a saturation prostate biopsy, do not file claims using non-specific codes 55700 or G0416 because they are not specific to saturation sampling. If appropriate, use CPT 55706 (transperineal stereotactic template saturation sampling, including imaging guidance). Note that the policy deems saturation biopsy not covered/not medically necessary for diagnosis, staging, and management of prostate cancer.

55706
55700
G0416

Documentation Required

Benefits/coverage verification

Benefits and coverage for saturation biopsy may vary between groups and contracts. Providers must refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable coverage determinations.

Background & Evidence Summary

Saturation biopsy involves obtaining a higher number of cores than standard or extended schemes (typically >20) and may improve sampling of anterior prostate zones; it can be performed transrectally or via a transperineal stereotactic template-guided approach. Studies and a 2013 systematic review found higher overall cancer detection rates with saturation versus extended schemes in some settings, but evidence did not report improvements in health outcomes (such as progression or survival) or reliably demonstrate increased detection of clinically significant cancers. In repeat-biopsy and active surveillance settings, saturation yields higher detection rates in some studies but also identifies a proportion of clinically insignificant cancers, which raises concern for potential overtreatment. The policy concludes that saturation biopsy is not covered / not medically necessary for diagnosis, staging, and management of prostate cancer because the evidence is insufficient to show an improvement in net health outcome; when performed, CPT code 55706 is the specific code listed and claims should not be filed with non-specific codes such as 55700 or G0416.

Evidence	Summary
Systematic review (2013)
Found higher cancer detection rates with saturation versus extended overall; in subgroup PSA <10 ng/mL the difference was small and possibly not clinically significant; health outcomes (eg, survival) were not reported.
Post-review studies
Several studies published after the systematic review did not show that initial saturation improved detection of clinically significant cancers and none reported progression or survival outcomes.
Repeat biopsy studies
Saturation biopsy in the repeat-biopsy setting showed higher detection rates versus standard biopsy, but about one-third of positives in at least one study were clinically insignificant; studies focused on detection rates and did not report health outcomes (eg, progression or survival).

Saturation biopsy

DefinitionProstate biopsy strategy generally involving more than 20 cores with improved sampling of anterior zones; may be transrectal or transperineal stereotactic template-guided.